Clinical research

Transendocardial autologous bone marrow in myocardial infarction induced heart failure, two-year follow-up in an open-label phase I safety study (the TABMMI study)

EuroIntervention 2011;7:805-812. DOI: 10.4244/EIJV7I7A127

Luis de la Fuente
Luis M. de la Fuente1, MD; Simon H. Stertzer2, MD; Julio Argentieri1, MD; Eduardo Peñaloza1, MD; Benjamin Koziner1, MD; Didier Rouy3, MD, PhD; Peter A. Altman3*, PhD
1. Instituto Argentino de Diagnostico y Tratamiento, Buenos Aires, Argentina; and Clinica Suizo Argentina, Buenos Aires, Argentina; 2. Stanford University Medical Center, Stanford, CA, USA; 3. BioCardia Inc., San Carlos, CA, USA

Aims: To assess the hypothesis that fluoroscopically-guided helical needle transendocardial delivery of autologous bone marrow (ABM) mononuclear cells (MNCs) in chronic p

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

heart failurecell therapycatheterstransplantation
Read next article
Evaluating the safety of very short-term (10 days) dual antiplatelet therapy after Genous™ bio-engineered R stent™ implantation: the multicentre pilot GENOUS trial

Latest news